Nassim Anjidani

Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations

Payam Tabarsi, Nassim Anjidani, Ramin Shahpari et al. · Clinical Microbiology and Infection · 2022 · 48 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +9

Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2–adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial

Payam Tabarsi, Nassim Anjidani, Ramin Shahpari et al. · Clinical Microbiology and Infection · 2022 · 48 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +10

Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS‐CoV‐2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo‐controlled trial

Payam Tabarsi, Nassim Anjidani, Ramin Shahpari et al. · Immunology · 2022 · 41 citations · Full text

Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial

Reza Malekzadeh, Atefeh Abedini, Behzad Mohsenpour et al. · International Immunopharmacology · 2020 · 37 citations · Full text

Long Covid, Covid-19 Pandemic, Subcutaneous Tocilizumab +6

Efficacy and Safety of Proposed Bevacizumab Biosimilar BE1040V in Patients With Metastatic Colorectal Cancer: A Phase III, Randomized, Double-blind, Noninferiority Clinical Trial

Hamid Rezvani, Seyed Mohammadreza Mortazavizadeh, Abolghasem Allahyari et al. · Clinical Therapeutics · 2020 · 15 citations